Taysha doses second Rett syndrome patient with TSHA-102 in REVEAL Phase 1/2 adult trial

Taysha Gene Therapies, Inc.

Second adult patient dosed with TSHA-102 in REVEAL Phase 1/2 adult trial for Rett syndrome in Canada.
Clinical data from both low-dose adult patients to be reported on mid-November earnings call after IDMC review.
Enrollment completion in low-dose cohort (third patient) expected Q4 2023.
First pediatric patient dosing expected Q1 2024; FDA cleared pediatric IND.
UK MHRA CTA for pediatric patients submitted; feedback expected H2 2023.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.